Company intelligence / Profile preview
Lobe Sciences Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
Lobe Sciences has achieved first-in-human clinical data with its oral psilocin candidate L‑130, demonstrating improved pharmacokinetics and shelf stability. Its medical food product Altemia® generated CAD $1.1M in sales in 2023 and is commercially available for Sickle Cell Disease. The company’s lead pharmaceutical program, Conjugated Psilocin™, targets chronic cluster headache and has secured new patent protection; it is advancing through early clinical stages with recent funding to support Phase 1/2a studies[3][5][7].
- Therapeutic areas
- HematologyNeurology
- Modalities
- Small molecules (notably stabilized/conjugated psilocin compounds)Medical foods[6][3]
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Lobe Sciences Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lobe Sciences Ltd..